# Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan

> **NCT01318083** · PHASE2,PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 312 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin and glimepiride
- **DRUG:** Alogliptin and glimepiride
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01318083
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318083, "Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01318083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*